Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries

IMPORTANCE: Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective but expensive. Evidence is scarce on whether DAA therapy reduces downstream medical costs. OBJECTIVE: To examine the association of DAA therapy with posttreatment medical costs among Medicare beneficiaries. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jeah, Feldman, Roger, Kalidindi, Yamini, Riley, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327546/
https://www.ncbi.nlm.nih.gov/pubmed/32602909
http://dx.doi.org/10.1001/jamanetworkopen.2020.8081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327546/
https://www.ncbi.nlm.nih.gov/pubmed/32602909
http://dx.doi.org/10.1001/jamanetworkopen.2020.8081

Ejemplares similares